Killestein Joep, Uitdehaag Bernard M J, Polman Chris H
Department of Neurology, VU Medical Center, Amsterdam 1007 MB, The Netherlands.
Drugs. 2004;64(1):1-11. doi: 10.2165/00003495-200464010-00001.
This is an exciting time for cannabinoid research. Evidence suggests that cannabis (marijuana) can alleviate symptoms like muscle spasticity and pain in patients with multiple sclerosis (MS). Interest in the field of cannabinoids has been strengthened by the identification and cloning of cannabinoid receptors located in the central nervous system and the peripheral immune organs, and by the discovery of the endogenous cannabinoid ligands. Cannabinoids are also efficacious in animal models of MS. However, there have been only ten published clinical reports on the use of cannabis in MS, involving 78 individuals worldwide, and the results have been equivocal. Researchers encounter a number of difficulties in designing clinical studies that use cannabinoids. From the studies reporting the use of cannabinoids in MS patients with spasticity, the somewhat better designed studies failed to demonstrate objective improvement. Therefore, convincing evidence that cannabinoids are effective in MS is still lacking.
这是大麻素研究令人兴奋的时期。有证据表明，大麻（ marijuana ）可缓解多发性硬化症（ MS ）患者的肌肉痉挛和疼痛等症状。位于中枢神经系统和外周免疫器官中的大麻素受体的鉴定与克隆以及内源性大麻素配体的发现，增强了人们对大麻素领域的兴趣。大麻素在 MS 的动物模型中也有效。然而，关于在 MS 中使用大麻的临床报告仅发表了十篇，涉及全球 78 人，结果并不明确。研究人员在设计使用大麻素的临床研究时遇到了许多困难。从报告在有痉挛的 MS 患者中使用大麻素的研究来看，设计稍好的研究未能证明有客观改善。因此，仍缺乏令人信服的证据证明大麻素对 MS 有效。
